# Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

> **NCT01152788** · PHASE2 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 64 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** rIL-21
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT01152788
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-05
- **Primary completion:** 2014-11-25
- **Final completion:** 2015-02-13
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2023-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01152788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01152788, "Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT01152788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*